{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-117243","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.484565+00:00","generated_at":"2026-05-30T00:52:59.860603+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cognition Therapeutics Q3 net loss $9.9M; CT1812 slows decline 95% in Alzheimer's sub-group","bullets":["Net loss $9.9M ($0.25/share) vs $6.7M ($0.22/share) in Q3 2023; cash $22M plus $53.6M NIA grants.","CT1812 showed 95% slowing of cognitive decline (ADAS-Cog11) in Alzheimer's patients with low p-tau217 at CTAD.","On track to report Phase 2 SHIMMER topline results in dementia with Lewy bodies by end of 2024.","Plans to request end-of-Phase 2 FDA meeting for CT1812 Alzheimer's program.","Cash runway into Q2 2025; R&D expense $11.4M, G&A $3.1M both flat YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-117243","json":"https://secwatch.observer/filing/0001104659-24-117243.json","markdown":"https://secwatch.observer/filing/0001104659-24-117243.md","text":"https://secwatch.observer/filing/0001104659-24-117243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924117243/0001104659-24-117243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924117243/tm2428074d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:52:59.860603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}